Downregulation of MEIS1 impairs long-term expansion of CD34
þ NPM1-mutated acute myeloid leukemia cells Leukemia (2012) Mutations of the nucleophosmin gene (NPM1) occur in about 30% of all acute myeloid leukemia (AML) patients and cause aberrant accumulation of NPM1 in the cytoplasm of leukemic cells (NPMc þ AML). 1 It is currently unclear how mutant NPM1 contributes to leukemic transformation and which molecular mechanisms underlie self-renewal of stem cells in NPMc þ AML. In most cases the leukemia initiating cells (LICs) have been found to reside in the CD34 þ fraction. As the vast majority of the leukemic cells within NPMc þ AML are negative for CD34, it remained unclear whether the generally accepted CD34 þ expression profile of LICs would also apply to NPMc þ AML. Recently, this question has been addressed by two research groups. Taussig et al. 2 describe that the CD34 À fraction of NPMc þ AML contains cells that could engraft immunocompromised mice in all studied samples, whereas Martelli et al. 3 showed that in most cases the CD34 þ , but not CD34 À cells generated NPMc þ AML in immunocompromised mice. NPMc þ AML has a unique gene expression profile, which is characterized by upregulation of HOX genes and MEIS1. 4, 5 It has been hypothesized that the (re)activation of a stem cell-like HOX gene signature in NPMc þ AML might contribute to the leukemic transformation, but formal proof for this concept is currently lacking. Characteristics of the AML samples used for the present study and an overview of the performed experiments are shown in Supplementary Table 1. To investigate whether mutant NPM1 protein is present in both the CD34 þ and CD34 À cell fractions of NPMc þ AML, cells of six AML samples were sorted on the basis of CD34 expression (Figure 1a , for all methods see Supplementary Materials and Methods) and western blot analysis was performed. Using an antibody that specifically recognizes NPM1 mutant protein and not the wild-type (wt) protein, 6 it was shown that mutant NPM1 protein was expressed in both the CD34 þ and CD34 À AML cell fractions (Figure 1b ), indicating that both the CD34 þ and CD34 À subpopulation of NPMc þ AML belong to the leukemic clone. The lower expression level of NPM1 and NPM1 mutant in CD34
À cells might be a reflection of the more differentiated state of the CD34 À AML cells compared with CD34 þ AML cells. 7 The presence of the NPM1 mutation in the CD34 þ /CD38 À fraction of NPMc þ AML was shown by western blot analysis of two AML samples (Figure 1c) .
To investigate whether long-term ex vivo expansion and selfrenewal properties reside in the CD34 þ or CD34 À population within NPMc þ AML samples, cells were sorted on the basis of CD34 expression and long-term co-cultures were initiated on MS5 bone marrow stromal cells. 8, 9 No long-term expanding cultures could be established with CD34
À NPMc þ cells (Figure 1d ). In contrast, when co-cultures were initiated with CD34
þ NPMc þ cells, a strong expansion (5-474 fold) was observed within the first 5 weeks in 80% of investigated cases (Figure 1d ). This expansion was associated with the formation of cobblestone areas under the stromal layer within 3 weeks after plating (Figure 1e ). The rate of expansion was independent of the presence of FLT3-ITD.
In order to assess the self-renewal capacity of expanding cultures, serial replating experiments were performed. After 5 weeks of co-culture of AML cells on MS5, the leukemic suspension and adherent cells were isolated on the basis of human CD45 expression and cells were replated onto new MS5 stroma. In seven out of nine investigated cases, which were initiated with CD34
þ NPMc þ AML cells, replated cells were capable of initiating second expanding cultures, whereby new leukemic cobblestone areas were formed underneath the stroma (Figure 1e ). Indeed, some CD34
þ NPMc þ AML cells could be maintained up to 20 weeks. The leukemic origin of the expanded replated cells was confirmed by showing the presence of mutant NPM1 protein by western blotting in three examined cases (data not shown). To investigate whether CD34
þ NPMc þ cells can give rise to CD34 À progeny, expanding NPMc þ AML cases (n ¼ 5) were analyzed for the percentage of CD34 þ cells by Fluorescence-activated cell sorting. Although the cultures were initiated with sorted CD34 þ cells with a purity of 495%, the percentage of CD34 dropped again to relatively low levels (0.22-4%) within 3 weeks upon in vitro culturing in all cases, suggesting that a new hierarchy within the leukemic clone was formed. To further investigate this hierarchy, replating experiments were performed with cultured expanding cells again sorted on the basis of CD34 expression before replating (n ¼ 4, Supplementary Table 1) . Indeed, only CD34 þ cells were able to expand in a secondary and tertiary replating experiment and gave rise to CD34 À progeny ( Figure 1f ). In contrast, CD34 À cells were not able to expand after replating, even when 100 000 cells were replated. Annexin V/PI apoptosis assays showed that a number of CD34 À replated cells went into apoptosis within 4 weeks after plating (6.7-36% Annexin V-positive cells) (data not shown).
As our data indicated that in vitro long-term self-renewing cultures could only be established by the CD34 10 This comparison resulted in the identification of 267 differentially expressed probesets with a P-valueo1 Â 10 -6 (Supplementary Table 3) . A supervised cluster analysis is shown in Figure 2a . Out of 267 genes, 88 were downregulated and 179 were upregulated in the NPMc þ CD34 þ group. Gene ontology analysis revealed that the upregulated gene list was strongly and significantly enriched for homeobox genes of the A and B clusters. The cofactors MEIS1 and 
The increased expression of MEIS1, HOXA9 and HOXB5 in NPMc þ AML compared with NPMwt AML was confirmed by real-time qRT-PCR. The colored dots indicate the AML IDs (indicated in the legend), two of these AMLs were used in the experiments shown in Figure 3c .
Letters to the Editor PBX3 were also amongst the upregulated genes, as well as the transcriptional regulators MSI2, JUND, GFI1 and RUNX1.
Second, we analyzed the differences in gene expression between CD34 
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Remarkably, we observed that the strong upregulation of HOX genes and MEIS1 was not only present in the self-renewing CD34 þ fraction, but also in the non-expanding CD34 À fraction of NPMc þ AML. Although the HOX genes and MEIS1 were consistently expressed higher in NPMc þ CD34 þ cells compared with NPMc þ CD34 À cells, these differences did not reach significance (Figure 2c ). The increased expression of MEIS1, HOXA9 and HOXB5 in NPMc þ AML compared with NPM1wt AML was confirmed by qualitative reverse transcriptase-PCR (qRT-PCR) (Figure 2d) .
The observation that the expression of HOX genes and MEIS1 was also elevated within the CD34 À NPMc þ compartment prompted us to determine whether HOXA/MEIS1 signaling would be required at all for the expansion of NPMc þ CD34 þ AML cells. To address this question, downregulation of MEIS1 was achieved by lentiviral transduction of a short hairpin targeting MEIS1 (shMEIS1). 12 Downregulation of MEIS1 expression was confirmed by qRT-PCR as well as western blotting (Figure 3a) . Downregulation of MEIS1 in the NPMc þ AML cell line OCI-AML3 induced a strong growth reduction in these cells compared with cells transduced with a control scrambled short hairpin (shSCR) (Figure 3b ). The reduced growth could at least partly be explained by increased apoptosis as examined by Annexin V/PI-staining (Supplementary Figure 1A) . Assessment of differentiation and cell cycle showed no distinct differences between shSCR-and shMEIS1-transduced OCI-AML3 cells (Supplementary Figure 1B and 1C ) . Moreover, the expression of mutant and total NPM1 was not changed upon downregulation of MEIS1 and there were no indications for the involvement of senescence (Supplementary Figures 1D and 1E) . Importantly, shMEIS1 transduction had no effect on cell growth in the MEIS1-negative BaF3 cell line (Figure 3b) , excluding non-specific effects of shMEIS1 transduction, and only a minor effect in the NPM1 wt KG1a cells (Figure 3b ). To further examine the effect of MEIS1 downregulation in NPMc þ AML, primary CD34 þ NPMc þ AML samples were transduced with shMEIS1 and control shSCR, and expansion was evaluated in MS5 cocultures. Downregulation of MEIS1 resulted in a strong reduction in expansion of primary CD34
þ NPMc þ AML cells (Figure 3c) , strongly suggesting the requirement of MEIS1 expression for long-term expansion of CD34 þ NPMc þ AML cells. No distinct differences were observed in the expression of CD11b and CD15 between shSCR-and shMEIS1-transduced NPMc þ AML cells (Figure 3d ). The increase in apoptosis upon downregulation of MEIS1 could be confirmed in primary AML cells (Figure 3e) .
In the present study, we show that the CD34 þ , but not the CD34 À cells of NPMc þ are capable of long-term expansion and serial replating in our ex vivo stromal co-cultures. The CD34 þ cells gave rise to CD34 À leukemic progeny upon culturing and serial replating, whereas CD34 À cells never gave rise to CD34 þ cells, suggesting that the CD34 þ cells are at the top of the hierarchy in NPMc þ AML. In addition, our data clearly indicate that MEIS1 is an important factor in NPMc þ AML that is required for the long-term expansion of CD34
þ NPMc þ cells. Yet, MEIS1 appears not to be sufficient for long-term expansion of leukemic cells, because we also observed high MEIS1 expression in the non-self-renewing CD34 À cells of NPMc þ AML. Thus, the cellular context in which HOX/MEIS1 is overexpressed appears to be very important, and other relevant genes are most likely required as well to maintain the expanding capacity of the CD34 þ NPMc þ AML cells. In this perspective, the potential new target genes of NPMc þ AML that could be identified by specifically studying gene expression profiles in the CD34
þ NPMc þ AML cells are of interest. Our future studies will be aimed at the elucidation of the specific role that the identified genes might fulfill in NPMc þ leukemia. Nucleophosmin1 (NPM1), located at 5q35.1, is frequently mutated, deleted or translocated in a number of hematopoietic malignancies. 1 Deletion of 5q encompassing the NPM1 locus occurs in B40% of high-risk myelodysplastic syndrome (MDS)/ acute myeloid leukemia (AML) with complex karyotypes, 2 although the common 5q interstitial deletion that occurs in MDS does not include this region. 3 Mice genetically engineered to harbor heterozygous loss of Npm1 (Npm1 þ /À) were shown to have a mild MDS-like phenotype characterized by dyserythropoiesis and dysplastic megakaryocytes with macrocytic anemia, but without significant cytopenias or alterations in lineage commitment. These mice also exhibited increased susceptibility to hematological malignancies with age. 4, 5 Although these studies confirmed NPM1's role as a tumor suppressor, they did not characterize a role for NPM1 in hematopoietic stem or progenitor cell function, a likely phenotype alteration given the propensity of NPM1 mutant mice to develop hematological neoplasms. To better understand the effects of loss of a single NPM1 allele on hematopoiesis, we obtained Npm1 heterozygous deficient mice (#11744-UCD) from the Mutant Mouse Regional Resource Centre (UC Davis, CA, USA). An embryonic stem cell clone with a single-gene trap event in the Npm1 locus was used to generate the Npm1 þ /À line (genetic background 129/SvEvBrd Â C57BL/6J).
Western blot analysis of cell lysates from total bone marrow cells demonstrated B50% reduction in NPM1 protein levels in hematopoietic cells in Npm1 þ /À mice as compared with wildtype controls (Supplementary Figure 1) . This reduction is similar to that reported in the previously characterized Npm1 þ /À mutant. 4 Complete loss of Npm1 (Npm1À/À) resulted in embryonic lethality as reported previously; 4, 6 however, Npm1 þ /À mice were viable, grossly normal and born at expected Mendelian ratios (Npm1 þ / þ :Npm1 þ /À:Npm1À/À ratios of 1:2.4:0; c 2 ¼ 0.86, P40.3). Next, we evaluated Npm1 þ /À mice for alterations in hematopoiesis. Complete blood counts did not differ significantly between age-matched Npm1 þ / þ and Npm1 þ /À mice (Supplementary Figure 2) . This result is in contrast to a previous report showing alterations in red blood cell size and anisocytosis. 4 In addition, the number of bone marrow cells per femur did not differ between Npm1 þ / þ and Npm1 þ /À mice, regardless of age (data not shown). Flow cytometric analysis revealed no significant change in the absolute number or relative percentage of mature myeloid (Gr-1 þ , Mac1 þ ) or lymphoid (B220 þ or CD3 þ ) cells (Supplementary Figure 3A, data not shown) in Npm1 þ /À mice as compared with wild-type littermates (up to 2 years of age). Evaluation of erythroid cells using CD71 and Ter119 antibodies revealed that the percentage of mature Ter119 þ , CD71 À erythroid cells (calculated as a percentage of total bone marrow cells) was significantly decreased, as previously reported (Supplementary Figure 3B , Po0.05 in Npm1 þ /À mice); however, in contrast to this prior report, the immature CD71 þ Ter119 þ erythroid cell population was unaffected (Po0.3).
As NPM1 loss-of-function is associated with the development of hematological malignancies containing stem-cell-like populations, we asked whether Npm1 haploinsufficiency affects hematopoietic stem cell (HSC) function (Figure 1 ). The number of HSCs in the bone marrow exhibited a small, but statistically significant increase (1.4-fold) in the percentage of HSCs (Lin-cKit þ Sca-1 þ CD34ÀCD150 þ) within the Lin-cKit þ Sca þ population of 12 Npm1 þ /À mice as compared with 13 wild-type littermate controls (Figure 1b ; Po0.01). In addition, the absolute number of HSCs was significantly increased (1.8-fold; Figure 1c ; Po0.04). The expansion in HSC numbers persisted as mice aged from 4 to 20 months. These data suggest that the level of Npm1 expression has a role in regulating HSC numbers in the bone marrow.
To determine whether functional differences exist between Npm1 þ / þ and Npm1 þ /À HSC, we examined the ability of HSC to form colonies in vitro. Using double FACS-sorted HSC, the total number and frequency of methylcellulose colony-forming unit (CFU)-granulocyte/monocyte and CFUgranulocyte/erythrocyte/monocyte/megakaryocyte were similar between Npm1 þ / þ (n ¼ 8) and Npm1 þ /À HSC (n ¼ 9; Supplementary Figure 4A) . Similarly, clonal HSC liquid culture assays did not show differences in plating efficiency, cell number or lineage composition when grown in myeloidpromoting conditions (data not shown). Together, these data indicate that Npm1 haploinsufficiency does not impair HSC survival, differentiation or growth in vitro, an observation that is consistent with the normal peripheral blood cell counts in Npm1 þ /À mice. As the increased HSC cell number in Npm1 þ /À mutant mice may be due to NPM1 effects on HSC self-renewal, colonies from methylcellulose assay were harvested and serial replating assays were performed for four rounds with 10 000 cells, with each round of replating occurring after 10 days. No significant differences in the number of colonies were observed during serial replating of HSCs from Npm1 þ / þ (n ¼ 3) and Npm1 þ /À (n ¼ 3) mice (Supplementary Figure 4B ).
As the increased numbers of HSC observed in Npm þ /À mice may be due to increased growth or decreased cell death, we determined whether Npm1 þ /À HSC (Lin-cKit þ Sca1 þ CD34ÀCD150 þ ) exhibit increased cell cycling. Evaluation of HSC cell cycle status in Npm1 þ / þ (n ¼ 4) and Npm1 þ /À (n ¼ 7) mice using Ki67 and 4 0 ,6-diamidino-2-phenylindole (DAPI) staining revealed no significant difference in their cell cycle distribution (Figures 2c and d) . The majority of both Npm1 þ / þ and Npm1 þ /À HSC were in a quiescent state (Ki67À, DAPIÀ) and fewer than 15% cells were in the G1 phase
